ABBV vs NBIS: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Nebius Group N.V. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-18.
AbbVie Inc. Β· Healthcare
$261.70
-1.0% upside to fair value
Med Conviction Grade C High Quality
VS
Nebius Group N.V. Β· Technology
$217.99
+45.0% upside to fair value
Med Conviction Grade B
QuantHub Verdict
NBIS has more upside to fair value (+45.0%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ABBV NBIS
Current Price $261.70 $217.99
Fair Value Estimate $259.04 $316.09
Upside to Fair Value -1.0% +45.0%
Market Cap $462.4B $52.3B
Forward P/E β€” β€”
EV / EBITDA 24.8x 56.8x
Price / Sales 7.2x 38.6x
Price / FCF 23.6x β€”
Revenue Growth YoY +10.2% +454.0%
Gross Margin 71.5% 58.6%
Operating Margin 29.3% -49.3%
Return on Equity -136.5% 0.9%
Dividend Yield 2.61% 0%
FCF Yield 4.25% β€”
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
ABBV β€” AbbVie Inc.
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
NBIS β€” Nebius Group N.V.
Nebius Group N.V. is an Amsterdam-based AI infrastructure company, formerly Yandex N.V., that builds end-to-end GPU cloud clusters, cloud platforms and developer tools for demanding AI workloads, alongside Toloka AI data solutions, TripleTen education and Avride autonomous driving. The business is growing explosively, with revenue up 454.0% year over year in the most recent quarter, and it has de…
Accumulation Zones
Metric ABBV NBIS
Zone Low $194.28 $237.07
Zone High $220.18 $268.68
In Buy Zone? No Yes
← ABBV Research    NBIS Research β†’    All Research